Advertisement

Quality of Life Research

, Volume 8, Issue 3, pp 263–268 | Cite as

Quality of life assessment in adults with type 1 Gaucher disease

  • Bruce J. Masek
  • Katherine B. Sims
  • Catherine M. Bove
  • Mark S. Korson
  • Priscilla Short
  • Dennis K. Norman
Article

Abstract

The effect of enzyme replacement therapy on health-related quality of life in 25 adults with type 1 Gaucher disease was investigated over a 2-year period. Quality of life was assessed using the SF-36 Health Survey (SF-36). Psychological functioning was assessed using the Symptom Checklist-90R. The results indicated significant improvement in 7 of 8 SF scale scores beginning at 18 months of therapy (P<0.05 to 0.001). The SF scale showing improvement first was Vitality (energy level and fatigue) at 6 months of therapy (P<0.01). The SF-36 scales showing the largest improvements were Role-Physical and Social Functioning (P<0.001). Compared to the general US adult population, the study population's health profile was significantly lower prior to starting therapy but by 24 months of therapy there were no differences between the two. No differences were found in psychological functioning compared to a US adult normative group at the start of therapy. However, within the study population there was significant improvement in mood and global functioning and fewer psychological symptoms reported at 24 months of therapy. The findings indicate that enzyme replacement therapy for type 1 Gaucher disease has a positive impact on health-related quality of life from the patient's perspective.

Enzyme replacement therapy Gaucher disease Quality of life 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science 1992; 256: 794±799.Google Scholar
  2. 2.
    Barton NW, Brady RO, Dambrosia JM et al. Re-placement therapy for inherited enzyme de®ciency ± macrophage-targeted glucocerebrosidase for Gaucher's disease. New Eng J Med 1991; 324: 1464±1470.Google Scholar
  3. 3.
    Zimran A, Kay A, Gelbart T et al. Gaucher disease: clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992; 71: 337±353.Google Scholar
  4. 4.
    NIH Technology Assessment Panel on Gaucher Dis-ease. Gaucher disease: current issues in diagnosis and treatment. J Amer Med Assoc 1996; 275: 548±553.Google Scholar
  5. 5.
    Mankin HJ, Doppelt SH, Rosenberg AE, Barranger JA. Metabolic bone disease in patients with Gaucher's disease. In: Avioli LV, Krane SM (Eds). Metabolic bone disease and clinically related disorders. Philadel-phia: WB Saunders, 1990: 730±752.Google Scholar
  6. 6.
    Barton NW, Furbish FS, Murray GJ, Gar®eld M, Brady RO. Therapeutic response to intravenous infu-sions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990; 87: 1913±1916.Google Scholar
  7. 7.
    Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: effcacy and adverse e.ects in 33 patients treated for 6 to 24 months. Blood 1993; 82: 408±416.Google Scholar
  8. 8.
    Clarke AE, Goldstein MK, Michelson D, Garber AM, Lenart LA. The e.ect of assessment method and re-spondent population on utilities elicited for Gaucher disease. Qual Life Res 1997; 6: 169±182.Google Scholar
  9. 9.
    Garber AM. No price too high? New Engl J Med 1992; 327: 1676±1678.Google Scholar
  10. 10.
    Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Annals of Internal Medicine 1993; 118: 622±629.Google Scholar
  11. 11.
    Lubeck DP, Litwin JM, Henning JM, Carroll PR. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res 1997; 6: 385±392.Google Scholar
  12. 12.
    Sutherland HJ, Till JE. Quality of life assessments and levels of decision making: di.erentiating objectives. Qual Life Res 1993; 2: 297±303.Google Scholar
  13. 13.
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey manual and interpretation guide. Boston: New England Medical Center, The Health Institute, 1993.Google Scholar
  14. 14.
    Derogatis LR. SCL-90-R: administration, scoring and procedures manual. Minneapolis: National Computer Systems, 1994.Google Scholar
  15. 15.
    Mosteller F, Ware JE, Levine S. Final panel: comments on the conference on advances in health status assess-ment. Medical Care 1989; 27: S283±294.Google Scholar
  16. 16.
    Cohen J. Statistical power for the behavioral sciences. Hillsdale, NJ: Lawrence Earlbaum Associates, 1988.Google Scholar
  17. 17.
    Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: skeletal re-sponses to macrophage-targeted glucocerebrosidase. Pediatrics 1995; 96: 629±637.Google Scholar
  18. 18.
    Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type 1 Gaucher disease. Journal of Bone and Mineral Research 1996; 11: 1801±1807.Google Scholar
  19. 19.
    Croog SH, Levine S, Testa MA et al.The e.ects of antihypertensive therapy on the quality of life. New Engl J Med 1986; 314: 1157±1664.Google Scholar
  20. 20.
    Lenderking WR, Gelber RD, Cotton DJ et al. Eval-uation of the quality of life associated with zidovu-dine treatment in asymptomatic human immunode®ciency virus infection. New Engl J Med 1994; 330: 738±743.Google Scholar
  21. 21.
    Meyer KB, Espindle DM, DeGiacomo JM, Jenuleson CS, Kurtin PS, Davies AR. Monitoring dialysis pa-tients' health status. Amer J Kidney Dis 1994; 24: 267±279.Google Scholar
  22. 22.
    Derogatis LR, Derogatis MF. SCL-90-R and the BSI. In: Spilker B (ed). Quality of life and pharmacoeco-nomics in clinical trials. Philadelphia: Lippincott-Ra-ven, 1996: 323±335.Google Scholar
  23. 23.
    Patrick DL, Deyo RA. Generic and diseae-speci®c measures in assessing health status and quality of life. Medical Care 1989; 27: S217±S232.Google Scholar
  24. 24.
    Cella D, Tulsky S. Measuring quality of life today: methodological aspects. Oncology 1990; 4: 29±38.Google Scholar
  25. 25.
    Sprangers MAG, Aaronson NK. The role of health care providers and signi®cant others in evaluating the quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992; 45: 743±760.Google Scholar
  26. 26.
    Bech P. Quality of life measurements in chronic dis-orders. Psychotherapy and Psychosomatics 1993; 59: 1±10.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Bruce J. Masek
    • 1
  • Katherine B. Sims
    • 2
  • Catherine M. Bove
    • 2
  • Mark S. Korson
    • 3
  • Priscilla Short
    • 4
  • Dennis K. Norman
    • 5
  1. 1.Division of Psychology, Department of PsychiatryChildren's HospitalBostonUSA
  2. 2.Division of Neurogenetics, Department of NeurologyMassachusetts General HospitalBostonUSA
  3. 3.Division of Genetics, Department of MedicineChildren's HospitalBostonUSA
  4. 4.Office of Biomedical Science and Clinical ResearchAmerican Medical AssociationChicagoUSA
  5. 5.Division of Psychology, Department of PsychiatryMassachusetts General HospitalBostonUSA

Personalised recommendations